Search

© 2021 BioMarin. All rights reserved.

Investors & Media
NASDAQ: BMRN
Loading...
Stock Quote
NASDAQBMRN
Events
BofA Global Healthcare Conference 2021
Friday, September 17, 2021
12:35pm - 1:15pm EDT
Add to Calendar
Set Email Reminder

All Events

Press Releases
Sep 5, 2021
U.S. FDA Placed a Clinical Hold on BMN 307 Phearless Phase 1/2 Gene Therapy Study in Adults with PKU Based on Interim Pre-clinical Study Findings

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today that the U.S Food and Drug Administration (FDA) placed a clinical hold on the BMN 307 Phearless Phase 1/2 study. The Phearless study is...

All Press Releases

Investor Presentation

Download Presentation

A commitment to corporate responsibility.

We are committed to conducting our operations and managing our products in a responsible manner and in accordance with applicable laws, rules, and regulations. We regularly review our operations to improve efficiency and reduce environmental impact where appropriate.

 

Learn More

We take on the biggest challenges in rare disease.

Each drug candidate we pursue is guided by a fundamental understanding of the genetics and underlying biology of the condition it will address.

 

Learn More

Contact Us

Investor Relations
415-382-5731
IR@BMRN.com

Media & Press
415-455-7451
corporatecommunications2@BMRN.com

Email Alerts

Sign up for alerts to receive updates on company announcements, financial information and more! 


Subscribe